Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment of the day
    • InvAscent-led India...

    InvAscent-led India Life Sciences Fund raises Rs 25 crore for its New Fund

    GarimaWritten by Garima Published On 2019-02-02T16:16:11+05:30  |  Updated On 17 Aug 2021 12:49 PM IST

    InvAscent, famed for its early-stage backing of Gland Pharma and Health Care Global through the first fund Evolvence India Life Sciences Fund, will continue to focus on the same set of sectors and investments.


    MUMBAI: In another boost to the Indian healthcare and Pharmaceutical funding in India, India Life Sciences Fund, healthcare and pharmaceuticals-focused private equity fund has raised $250 million(Rs 25 crore) for its third growth capital fund. The fund is adviced by InvAscent.


    As preliminary indications, the fund is going to focus on quality and low costs medicines.

    "The demand for quality medicines and quality healthcare in India is very strong." "In addition, globally, there is a demand for high quality and low-cost medicines. And Indian firms are very good at addressing this demand," Hari Buggana, chairman and managing director of InvAscent Investment Advisors told ET.


    InvAscent is known in the investment circle for its early-stage backing of Gland Pharma and Health Care Global (HCG) through the first fund Evolvence India Life Sciences Fund will continue to focus on the same set of sectors and investments.


    In a strategic proceed, the company had invested Rs 120 crore in Gland Pharma in the year 2008 and later sold it at about Rs 1300 crore thereby gaining huge profit. Similarly, the firm has sold its stake in Healthcare Global to Singaporean sovereign fund Temasek. Further, it has made other investments in giants including medical equipment maker Sutures India and Dr Agarwals' Eye Hospital.


    ET recounts the history of this unique fund in healthcare. InvAscent's debut healthcare fund, Evolvence India Life Sciences Fund (EILSF), had raised $100 million in 2006 and was anchored by Dubai-based fund-of-funds manager Evolvence.


    The second fund, India Life Sciences Fund II, made the final close at Rs 875 crore ($143.2 million), against a target of Rs 750 crore, in September 2014.


    "Our Fund I made eight investments and has exited all of them successfully, which is quite remarkable in the current circumstances. From the second fund, we began investing in 2013, have made 12 investments and it is fully deployed," Buggana told the daily.


    Currently, the investors of the fund include blue chip fund-of-fund vehicles, pension funds and university endowments and family offices from the US and Europe.


    "The per-investment ticket size would be between $10 million and $50 million. We have already made three commitments from the third fund," Buggana added


    Other private equity funds operating in the healthcare space in India include Quadria Capital, Sabre Partners, Asian Healthcare Fund and Somerset Health Capital Advisors.


    Also Read: Strides to exit investment in Arrow Pharma for over Rs 2000 crore

    blue chip fundequity fundfundHealthcare NewsIndia Life Sciences FundIndian firm newsInvAscentInvestmentKKR investedlow cost drugspension fundpharma news in indiapharmaceutical news in IndiaPharmaceuticals
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok